Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis

Overview of attention for article published in Clinical Genitourinary Cancer, October 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 9 X users

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 16,128 followers.

RT @JapneetOberoi25: Excited to share our new study! Grateful to my mentors for their constant guidance and support. @Parminder1699 @Irba…

RT @prateekim7: Excited to share our new study. Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcino…

https://t.co/frAWPjfrxr Sharing the link again

RT @prateekim7: Excited to share our new study. Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcino…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.